🚨Exciting new press release in HR /HER2- breast cancer! Current standard of care for the past 20 years in early stage HR breast cancer has been endocrine therapy with tamoxifen or an aromatase inhibitor. In metastatic breast cancer, we are increasingly using oral SERDs, which are selective estrogen receptor degraders. SERDs work by binding to the estrogen receptor, which causes a conformational change that leads to the receptor’s degradation through the proteasome pathway. There are several SER

Researchers are investigating a potential new treatment option for young women with the most common type of breast cancer through our OLIO clinical trial. This study builds on a breakthrough that identified a feature in the tumours of young women with hormone receptor-positive, HER2-negative breast cancer - a type often more aggressive in premenopausal women. OLIO will test whether targeted treatments, including olaparib (alone or with durvalumab), when added to standard chemotherapy before surg